February 18-19th, 2014 | Frankfurt, Germany | World ADC

 

Antibody drug conjugates are an emerging class of biotherapeutics which has demonstrated a significant impact on clinical practice, highlighting the potential of this new class of targeted therapies. The World ADC Frankfurt 2014 is a great opportunity to discuss strategies, relevant achievements and remaining challenges to get ADCs into clinic.

 

Thanks to its outstanding patient-derived tumor xenografts (PDX) collection and its experience in testing ADCs, XenTech proposes to help selecting your lead candidate with confidence and improve preclinical predictability.

Jean-Gabriel Judde (CSO) and Sabrina Serpillon will be attending this meeting and will be glad to discuss with you how your strategy can be optmized to move your project forward.

 

Contact us and meet us at our booth!